» Articles » PMID: 20138414

Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: the AusDiab (Australian Diabetes, Obesity And...

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2010 Feb 9
PMID 20138414
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) is more accurate than the Modification of Diet in Renal Disease (MDRD) Study equation. We applied both equations in a cohort representative of the Australian adult population.

Study Design: Population-based cohort study.

Setting & Participants: 11,247 randomly selected noninstitutionalized Australians aged >or= 25 years who attended a physical examination during the baseline AusDiab (Australian Diabetes, Obesity and Lifestyle) Study survey.

Predictors & Outcomes: Glomerular filtration rate (GFR) was estimated using the MDRD Study and CKD-EPI equations. Kidney damage was defined as urine albumin-creatinine ratio >or= 2.5 mg/mmol in men and >or= 3.5 mg/mmol in women or urine protein-creatinine ratio >or= 0.20 mg/mg. Chronic kidney disease (CKD) was defined as estimated GFR (eGFR) >or= 60 mL/min/1.73 m(2) or kidney damage. Participants were classified into 3 mutually exclusive subgroups: CKD according to both equations; CKD according to the MDRD Study equation, but no CKD according to the CKD-EPI equation; and no CKD according to both equations. All-cause mortality was examined in subgroups with and without CKD.

Measurements: Serum creatinine and urinary albumin, protein, and creatinine measured on a random spot morning urine sample.

Results: 266 participants identified as having CKD according to the MDRD Study equation were reclassified to no CKD according to the CKD-EPI equation (estimated prevalence, 1.9%; 95% CI, 1.4-2.6). All had an eGFR >or= 45 mL/min/1.73 m(2) using the MDRD Study equation. Reclassified individuals were predominantly women with a favorable cardiovascular risk profile. The proportion of reclassified individuals with a Framingham-predicted 10-year cardiovascular risk >or= 30% was 7.2% compared with 7.9% of the group with no CKD according to both equations and 45.3% of individuals retained in stage 3a using both equations. There was no evidence of increased all-cause mortality in the reclassified group (age- and sex-adjusted hazard ratio vs no CKD, 1.01; 95% CI, 0.62-1.97). Using the MDRD Study equation, the prevalence of CKD in the Australian population aged >or= 25 years was 13.4% (95% CI, 11.1-16.1). Using the CKD-EPI equation, the prevalence was 11.5% (95% CI, 9.42-14.1).

Limitations: Single measurements of serum creatinine and urinary markers.

Conclusions: The lower estimated prevalence of CKD using the CKD-EPI equation is caused by reclassification of low-risk individuals.

Citing Articles

Impact of hospital-based early detection on management in chronic kidney disease: the CKD Stewardship study (CKD-S) - protocol for a prospective, multicentre, observational cohort study.

Wynter L, Smyth B, Saunders J, Moroney C, Gorringe L, Turner K BMJ Open. 2025; 15(3):e094554.

PMID: 40044204 PMC: 11883606. DOI: 10.1136/bmjopen-2024-094554.


Global, regional, and national burden of chronic kidney disease due to diabetes mellitus type 2 from 1990 to 2021, with projections to 2036: a systematic analysis for the Global Burden of Disease Study 2021.

Hu R, Zhao Z, Xie L, Ma Z, Wu W, Li S Front Med (Lausanne). 2025; 12:1531811.

PMID: 40034386 PMC: 11872908. DOI: 10.3389/fmed.2025.1531811.


The comprehensive relationship between combined anti-inflammatory and healthy diets and all-cause mortality in rheumatoid arthritis: results from NHANES 2003-2018.

Wang P, Wang D, Sui J, Liu S, Kong Y, Lei H Arthritis Res Ther. 2024; 26(1):226.

PMID: 39716234 PMC: 11665084. DOI: 10.1186/s13075-024-03462-y.


PREVALENCE, Characteristics, and Awareness of Chronic Kidney Disease in Croatia: The EH-UH 2 Study.

Jelakovic A, Radunovic D, Josipovic J, Zeljkovic Vrkic T, Gellineo L, Domislovic M J Clin Med. 2024; 13(22).

PMID: 39597972 PMC: 11594885. DOI: 10.3390/jcm13226827.


Apolipoprotein B-48 and late graft failure in kidney transplant recipients.

Szili-Torok T, de Borst M, Soteriou A, Post L, Bakker S, Tietge U Clin Kidney J. 2024; 17(10):sfae289.

PMID: 39430793 PMC: 11487158. DOI: 10.1093/ckj/sfae289.